Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | EVP, Chief Medical Officer | January 19, 2017 | January 24, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date January 19, 2017 · Filed January 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,608 |
Reported balance
After 2017-01-19 transaction · row 1
1 source rowRow 1 · 2017-01-19 · Grant · Acquired 17,985 · Balance 72,608 F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.90 · Expires 2027-01-19 | Direct | 74,233 |
Reported balance
After 2017-01-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-19 · Grant · Acquired 74,233 · Balance 74,233 F2: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 19, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof.
F2: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 19, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AGILE THERAPEUTICS INC
Report date August 26, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-26 · Disposition to issuer · Disposed 10,125 · Balance 3,375 F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 10,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $15,390, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Row 2 · 2024-08-26 · Disposition to issuer · Disposed 3,375 · Balance 0 F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 3,375 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $5,130, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 10,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $15,390, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person.
F2: Upon the consummation of the Merger, pursuant to the Merger Agreement, 3,375 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $5,130, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2024 Filed Aug 26, 2024 17:40 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 3,375 | $1.52 | $5,130.00 |
DisclosureSEC source: 0001104659-24-092944 · tm2422466-8_4seq1.xml · nonDerivative · entry 2 Korner Paul · CIK 0001663000 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Upon the consummation of the Merger, pursuant to the Merger Agreement, 3,375 shares of Common Stock were converted into the right to receive the Merger Consideration, for an aggregate of $5,130, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person. Read SEC document |
| August 26, 2024 Filed Aug 26, 2024 17:40 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | Disposition to issuerCommon Stock | 10,125 | $1.52 | $15,390.00 |
DisclosureSEC source: 0001104659-24-092944 · tm2422466-8_4seq1.xml · nonDerivative · entry 1 Korner Paul · CIK 0001663000 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,375 F1 · shares: Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 10,125 restricted stock units ("Agile RSUs") were cancelled and converted into the right to receive a cash payment of $1.52 (the "Merger Consideration") per Agile RSU, for an aggregate of $15,390, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock subject to such Agile RSU owned by the reporting person. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:38 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001104659-23-077177 · tm2320328-4_4seq1.xml · derivative · entry 2 Korner Paul · CIK 0001663000 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2033-06-27 F2 · derivative.exercise_date: This option was granted on June 28, 2023. 25% of the shares subject to the stock option vest on June 28, 2024, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on June 28, 2027. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 16:38 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-077177 · tm2320328-4_4seq1.xml · nonDerivative · entry 1 Korner Paul · CIK 0001663000 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 F1 · shares: These shares represent restricted stock units ("RSUs") which were granted on June 28, 2023. The RSUs will vest in four equal installments over four years upon the anniversary of the grant, such that the RSUs will be fully vested on June 28, 2027. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 16:35 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001104659-22-118639 · tm2230300-4_4seq1.xml · derivative · entry 1 Korner Paul · CIK 0001663000 · Sr. VP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-11-08 F1 · derivative.exercise_date: This option was granted on November 9, 2022. 25% of the shares subject to the stock option vest on November 9, 2023, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on November 9, 2026. Read SEC document |
| January 19, 2022 Filed Jan 20, 2022 21:31 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001104659-22-006129 · tm224102-2_4seq1.xml · derivative · entry 1 Korner Paul · CIK 0001663000 · Sr. VP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: This option was granted on January 19, 2022. 25% of the shares subject to the stock option vest on January 19, 2023, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 19, 2026. Read SEC document |
| January 27, 2021 Filed Jan 28, 2021 18:32 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 173,160 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001104659-21-008898 · tm214338-6_4seq1.xml · derivative · entry 1 Korner Paul · CIK 0001663000 · Sr. VP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,160 Underlying: Common Stock · 173,160 shares Expires 2031-01-26 F1 · derivative.exercise_date: This option was granted on January 27, 2021. 25% of the shares subject to the stock option vest on January 27, 2022, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on January 27, 2025. Read SEC document |
| August 17, 2020 Filed Aug 17, 2020 18:47 UTC | AGILE THERAPEUTICS INC AGRX · Entity 87994 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.87 | $0.00 |
DisclosureSEC source: 0001104659-20-096165 · a4.xml · derivative · entry 1 Korner Paul · CIK 0001663000 · Sr. VP & Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2030-08-16 F1 · derivative.exercise_date: This option was granted on August 17, 2020. 25% of the shares subject to the stock option vest on August 17, 2021, and the remaining shares vest in 36 substantially equal monthly installments over the following three years such that the option will be fully vested on August 17, 2024. Read SEC document |
| January 19, 2017 Filed Jan 24, 2017 01:49 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 74,233 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001140361-17-002600 · doc1.xml · derivative · entry 2 Korner Paul · CIK 0001663000 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,233 Underlying: Common Stock · 74,233 shares Expires 2027-01-19 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 19, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 19, 2017 Filed Jan 24, 2017 01:49 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 17,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-002600 · doc1.xml · nonDerivative · entry 1 Korner Paul · CIK 0001663000 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,608 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| January 05, 2017 Filed Jan 24, 2017 01:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6,130 | $12.95 | $79,383.50 |
DisclosureSEC source: 0001140361-17-002599 · doc1.xml · nonDerivative · entry 1 Korner Paul · CIK 0001663000 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,623 F1 · kind: The shares were automatically sold pursuant to the Issuer's 2014 Equity Incentive Award Plan to cover tax liability upon the vesting of outstanding Restricted Stock Units ("RSUs"). F2 · balance_after: Includes 45,565 RSUs. The reporting person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.